Viracept: Began multicenter Phase II/III trials

The trial will evaluate two doses, 500 and 750 mg given three times daily, mostly in combination with other anti-HIV drugs, including Glaxo-Wellcome's Retrovir ( AZT) and BioChem Pharma Inc.'s Epivir ( 3TC). ...